Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last €356.25 EUR
Change Today -1.13 / -0.32%
Volume 170.0
As of 5:13 AM 06/30/15 All times are local (Market data is delayed by at least 15 minutes).

biogen inc (IDP) Snapshot

Open
€353.04
Previous Close
€357.38
Day High
€360.02
Day Low
€353.04
52 Week High
03/23/15 - €447.80
52 Week Low
07/18/14 - €218.15
Market Cap
83.8B
Average Volume 10 Days
790.9
EPS TTM
--
Shares Outstanding
235.2M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for BIOGEN INC (IDP)

biogen inc (IDP) Details

Biogen Inc. discovers, develops, manufactures, and markets therapies for the treatment of neurological, autoimmune, and hematologic disorders in the United States and internationally. It provides AVONEX to treat relapsing multiple sclerosis (MS); TYSABRI to treat relapsing forms of MS and Crohn’s disease; PLEGRIDY to treat relapsing MS; TECFIDERA to treat MS; FAMPYRA to improve walking in adult patients with MS; ALPROLIX to treat hemophilia B; ELOCTATE to treat hemophilia A; RITUXAN for treating non-Hodgkin's lymphoma, rheumatoid arthritis, and chronic lymphocytic leukemia (CLL), as well as two forms of ANCA-associated vasculitis; GAZYVA for the treatment of patients with previously untreated CLL; and FUMADERM to treat severe plaque psoriasis in adult patients. The company’s products that completed Phase III clinical trials comprise ZINBRYTA, a monoclonal antibody in relapsing MS. Its products under Phase III clinical trials consist of TYSABRI for secondary progressive MS and spinal muscular atrophy; ISIS – SMN for spinal muscular atrophy; and GAZYVA for non-Hodgkin's lymphoma. The company’s Phase II clinical trial products include Anti-LINGO for optic neuritis and MS; Neublastin for neuropathic pain; TYSABRI for optic neuritis; ANTI-TWAEK for lupus nephritis; BAN2401 and E2609 for Alzheimer’s disease; and GAZYVA for lupus nephritis, as well as Phase IIa clinical trial products include STX-100 for idiopathic pulmonary fibrosis. Its Phase I clinical trial products comprise BIIB037 for Alzheimer's disease; ISIS – DMPK for myotonic dystrophy; BIIB061 for MS; and Anti-BDCA2 for systemic lupus erythematosus, as well as Phase Ib clinical trial products include BIIB037 for Alzheimer's disease and Anti-C for systemic lupus erythematosus. The company was formerly known as Biogen Inc. and changed its name to Biogen Inc. in March 2015. Biogen Inc. was founded in 1985 and is headquartered in Cambridge, Massachusetts.

7,550 Employees
Last Reported Date: 02/4/15
Founded in 1985

biogen inc (IDP) Top Compensated Officers

Chief Executive Officer and Director
Total Annual Compensation: $1.4M
Chief Financial Officer and Executive Vice Pr...
Total Annual Compensation: $698.4K
Chief Strategy Officer and Senior Vice Presid...
Total Annual Compensation: $2.3M
Executive Vice President of Research & Develo...
Total Annual Compensation: $766.8K
Executive Vice President of Global Commercial...
Total Annual Compensation: $675.1K
Compensation as of Fiscal Year 2014.

biogen inc (IDP) Key Developments

Biogen and Swedish Orphan Biovitrum AB (publ) Announce European Medicines Agency Validates Alprolix Marketing Authorization Application

Biogen and Swedish Orphan Biovitrum AB (publ) announced that the European Medicines Agency (EMA) has accepted the Marketing Authorization Application (MAA) of ALPROLIX (rFIXFc), a recombinant factor IX Fc fusion protein product candidate for the treatment of hemophilia B. This validation signifies the initiation of the EMA’s review process. The MAA includes results from two global, Phase 3 clinical trials examining the efficacy, safety and pharmacokinetics (a measure of the presence of the therapy in a person’s body over time) of ALPROLIX for hemophilia B: the pivotal B-LONG study for previously treated adults and adolescents, and Kids B-LONG study for previously treated children under age 12. ALPROLIX is a recombinant, clotting factor IX therapy and is currently approved for the treatment of hemophilia B in the U.S., Canada, Japan and Australia. It is the only approved hemophilia B therapy to demonstrate prolonged clotting factor circulation in the body. Biogen and Sobi are collaborators in the development and commercialization of ALPROLIX for hemophilia B. Sobi has an opt-in right to assume final development and commercialization of ALPROLIX for the Sobi territories (essentially, Europe, North Africa, Russia and certain Middle Eastern markets). Biogen leads development for ALPROLIX, has manufacturing rights, and has commercialization rights in North America and all other regions in the world excluding the Sobi territories.

Biogen Appoints Matt Griffiths as Senior Vice President and Chief Information Officer

Biogen has appointed Matt Griffiths, former vice president of pharmaceutical operations and corporate information technology, as the company's senior vice president and chief information officer. Griffiths will be charged with developing Biogen's strategy for information technology.

Biogen Inc. Presents at BIO International Convention 2015, Jun-17-2015 09:45 AM

Biogen Inc. Presents at BIO International Convention 2015, Jun-17-2015 09:45 AM. Venue: Pennsylvania Convention Center, Philadelphia, Pennsylvania, United States.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
IDP:GR €356.25 EUR -1.13

IDP Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Bristol-Myers Squibb Co $65.97 USD -1.57
Celgene Corp $114.91 USD -3.01
Eli Lilly & Co $83.78 USD -2.07
Medtronic PLC $73.30 USD -1.86
Novo Nordisk A/S kr365.10 DKK -0.70
View Industry Companies
 

Industry Analysis

IDP

Industry Average

Valuation IDP Industry Range
Price/Earnings 29.5x
Price/Sales 9.5x
Price/Book 8.2x
Price/Cash Flow 26.0x
TEV/Sales 9.2x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact BIOGEN INC, please visit www.biogenidec.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.